# Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

> **NCT03626896** · NA · COMPLETED · sponsor: **NaviFUS Corporation** · enrollment: 6 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Brain Tumor
- Glioblastoma
- Glioma
- Neoplasms
- Neoplasms, Nerve Tissue

## Interventions

- **DEVICE:** NaviFUS System

## Key facts

- **NCT ID:** NCT03626896
- **Lead sponsor:** NaviFUS Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-17
- **Primary completion:** 2019-05-20
- **Final completion:** 2019-06-19
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03626896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03626896, "Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03626896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*